Brokerages Set Teladoc Health, Inc. (NYSE:TDOC) Price Target at $7.54

Shares of Teladoc Health, Inc. (NYSE:TDOC) have been assigned an average rating of “Hold” from the sixteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $7.5357.

A number of brokerages recently commented on TDOC. Bank of America boosted their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Canaccord Genuity Group decreased their target price on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Citigroup lowered their price target on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd.

Teladoc Health Price Performance

Teladoc Health stock opened at $6.38 on Tuesday. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -6.45 and a beta of 2.12. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.89. The stock’s 50-day moving average is $7.97 and its 200-day moving average is $6.64.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.04. The company had revenue of $606.93 million during the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.19) earnings per share. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Research analysts anticipate that Teladoc Health will post -0.89 EPS for the current year.

Insider Transactions at Teladoc Health

In other news, insider Adam C. Vandervoort sold 7,906 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the sale, the insider directly owned 110,261 shares of the company’s stock, valued at $841,291.43. This trade represents a 6.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $145,977.16. Following the transaction, the chief executive officer directly owned 389,894 shares in the company, valued at approximately $2,974,891.22. The trade was a 4.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 39,195 shares of company stock valued at $299,058. 0.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Creative Planning boosted its position in Teladoc Health by 7.7% during the third quarter. Creative Planning now owns 20,567 shares of the health services provider’s stock worth $159,000 after purchasing an additional 1,462 shares during the period. Versant Capital Management Inc boosted its holdings in shares of Teladoc Health by 33.3% during the 2nd quarter. Versant Capital Management Inc now owns 8,207 shares of the health services provider’s stock worth $70,000 after buying an additional 2,052 shares during the period. Syon Capital LLC grew its stake in Teladoc Health by 19.1% in the 4th quarter. Syon Capital LLC now owns 14,140 shares of the health services provider’s stock valued at $99,000 after buying an additional 2,264 shares during the last quarter. ProShare Advisors LLC lifted its position in Teladoc Health by 8.2% during the 4th quarter. ProShare Advisors LLC now owns 32,532 shares of the health services provider’s stock worth $228,000 after acquiring an additional 2,457 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 2,810 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.